Two Directors at Illumina Inc bought 18,450 shares at between 80.864USD and 81.210USD. The significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the l...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Illumina, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 10 April 2025 in which we reassessed the appropriateness of the ratings in the context of th...
Moody's Ratings (Moody's) assigned a Baa3 rating to the new senior unsecured notes offering of Illumina, Inc. ("Illumina"). In addition, we assigned a (P)Baa3 rating to Illumina's new senior unsecured shelf registration statement. There are no changes to Illumina's existing Baa3 senior unsecured not...
Moody's Ratings (Moody's) affirmed the Baa3 issuer rating and senior unsecured ratings of Illumina, Inc. ("Illumina"). At the same time, Moody's revised the outlook to stable from negative. The revision of the outlook to stable reflects reduced negative pressure on Illumina's credit profile becaus...
Moody's Investors Service ("Moody's") has revised the outlook of Illumina, Inc. ("Illumina") to negative from stable. Concurrently, Moody's affirmed Illumina's Baa3 issuer and senior unsecured ratings. The revision of the outlook to negative reflects Moody's expectation that Illumina will operate ...
Moody's Investors Service, ("Moody's") assigned a Baa3 rating to the proposed offering of $1 billion of senior unsecured notes of Illumina, Inc ("Illumina"). There are no changes to Illumina's existing Baa3 issuer rating or the stable outlook. Proceeds of the offering will be used to repay upcomin...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Moody's Investors Service commented that the adverse verdict in a patent infringement lawsuit is credit negative but manageable for Illumina, Inc. Despite its large amount ($334 million), Illumina is in a position to absorb this large adverse monetary award thanks to $1.35 billion of cash on hand an...
The independent financial analyst theScreener just awarded an improved star rating to ILLUMINA (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as moderately risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date March 18, 2022, the closi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.